$DTIL

iECURE, Inc. announced that data from its OTC-HOPE clinical trial of ECUR-506 for neonatal-onset OTC deficiency will be presented at the SSIEM Annual Symposium. The presentation will include safety and metabolic control data. iECURE is a clinical-stage genome editing company, and Precision BioSciences (DTIL) is involved through its ARCUS nuclease technology.

PRECISION BIOSCIENCES INC (DTIL) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 q22026earningsrelease_final.htm EX-99.1 Document Exhibit 99.1 Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update - First clinical biopsy evidence of direct cccDNA elimination from ongoing Phase 1 ELIMINATE-B trial; PBGENE-HB

PRECISION BIOSCIENCES INC (DTIL) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. dtil-20260723 0001357874 FALSE 0001357874 2026-07-23 2026-07-23 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ________________________________________________________ FORM 8-K ________________________________________________________ CURRENT REPORT Pursua

PRECISION BIOSCIENCES INC (DTIL) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. dtil-20260610 0001357874 FALSE 0001357874 2026-06-10 2026-06-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ________________________________________________________ FORM 8-K ________________________________________________________ CURRENT REPORT Pursua

Precision BioSciences (DTIL) reported first clinical biopsy evidence from its ELIMINATE-B study that PBGENE-HBV can eliminate and inactivate hepatitis B cccDNA. The company said cccDNA transcripts fell 10-fold after two doses, with remaining cccDNA showing indels that disrupt viral polymerase. It also reported pgRNA as a biomarker and durable HBsAg declines up to a year; 38 doses in 16 patients showed no dose-limiting toxicities.

Precision BioSciences announced its first-quarter 2026 financial results, highlighting ongoing clinical progress for its gene editing programs PBGENE-HBV and PBGENE-DMD. The company reported a cash balance of $125.8 million, expected to fund operations and data milestones through 2028. Key advancements include expanding the ELIMINATE-B trial for PBGENE-HBV and activating the first clinical site for the FUNCTION-DMD trial for PBGENE-DMD, alongside positive updates from partnered programs.

Precision BioSciences, Inc. (Nasdaq: DTIL) has released an investor update on its PBGENE-DMD program for Duchenne muscular dystrophy, highlighting the program's advancement into a Phase 1/2 clinical trial following FDA IND clearance. The company anticipates initial safety and early efficacy data by year-end 2026 and expects a cash runway through at least the end of 2028. This update emphasizes the potential for PBGENE-DMD to address a significant unmet medical need and differentiate itself in a growing market.

Precision BioSciences CFO John Alexander Kelly sold 8,149 shares of the company's stock on February 18th for $3.84 per share, totaling $31,292. This transaction reduced his direct holdings by 6.08% to 125,883 shares. The article also notes significant institutional investment in Q4, mixed analyst ratings, and the company's current stock performance.

J. Jefferson Smith, an insider at Precision BioSciences (NASDAQ:DTIL), sold 4,925 shares of the company's stock for $18,912.00 on February 18th, reducing his stake by 3.88%. This sale follows another transaction on January 21st where he sold 10,200 shares. The stock traded up $0.07 to $3.92, with analysts holding a consensus "Hold" rating and a target price of $60.00.

Precision BioSciences ( NASDAQ:DTIL ) , a clinical-stage biotechnology firm focused on gene editing, released its Q2 FY2025 earnings results on August 7, 2025. The main headline: GAAP revenue dropped to $18 thousand, considerably underperforming the consensus GAAP estimate of $4.98 million, and ...